For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to ...

Geron unveiled its first-quarter numbers well before market open, showing that the oncology-focused biotech earned $39.6 million during the period. Nearly all of this was derived from sales of Rytelo, ...

Geron (GERN) has been beaten down lately with too much selling pressure. While the stock has lost 26.6% over the past four ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session. Geron stock ...

Geron Corp (NASDAQ:GERN) shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After decades of work and delay, Geron Corporation is finally approaching its first approval. That should be done by about H1 2024, and although the stock looks properly valued based on revenue ...

Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades. On June 6, the U.S. Food ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an ...

Geron stock is seeing huge sell-offs on the heels of the company's recent fourth-quarter report and commentary. Despite sales for the period coming in ahead of the market's expectations, the business ...